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• Of the 58 CDs, sheath placement was 
the most common procedural event 
attributed to CDs (N=34)
• Rate of endovascular repair was 
significantly higher in CDs requiring no 
additional access attempts
• Rate of open surgical repair was 
significantly higher in CDs with
persistent failure to obtain true lumen 
despite ≥2 access attempts
• Rate of stroke from either endovascular 
repair (N=1) or open surgical repair 
(N=1) was similar (p=1.00).
• 1 stroke from a hypotensive episode  
7 hours after endovascular CD repair
• 1 stroke during conversion to CEA
• No deaths were associated with CD and 
subsequent repairs
• Sheath placement was the most 
common procedural events 
associated with CD
• Rate of endovascular repair was 
significantly higher if no additional 
access attempts were needed
• Rateof open surgical repair was 
significantly higher for cases 
requiring multiple access attempts
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Table 1. Comparison of CD repair methods based on 
number of access attempts needed to reach the true lumen
Figure 1. Query of medical adverse reports related to TCAR  from MAUDE database 
OBJECTIVE
To characterize carotid 
artery dissections that result 
from TCAR procedure and 




MARs collected from the MAUDE 
database do not account for all TCAR 
procedures performed in the U.S.
• Transcarotid Artery 
Revascularization (TCAR):
reverses blood flow away from the 
brain while placing a stent through 
a direct, surgical access of the 
carotid artery.
• Carotid artery stenosis is a major 
cause of ischemic stroke.1 TCAR 
provides an alternative to carotid 
endarterectomy (the current gold 
standard for treatment).
• TCAR demonstrated the lowest 
perioperative stroke rate when 
compared to other similar 
methods of stent placement.2
• Carotid artery dissection (CD) is 
the most common TCAR 
complication, but its management 
has not been well characterized.3













Multiple Attempts (≥2 Attempts)











• Manufacturer And User Device 
Experience (MAUDE): FDA 
database designed for surveillance of 
all FDA-approved medical devices.
• This database was queried for 
Medical Adverse Reports (MARs) on 
Silk Road Medical’s ENROUTE 
Transcarotid Neuroprotection System 
(Oct. 2016 – Oct. 2020).
• All CDs identified intraoperatively 
were analyzed for:
• Number of access attempts for CD 
repair
• Type of repair (endovascular, 
surgical)
